RAFA
A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 70 patients (estimated)
- Sponsors
- Children's Hospital Medical Center, Cincinnati
- Collaborators
- Memorial Sloan Kettering Cancer Center, Fred Hutchinson / University of Washington Cancer Consortium
- Tags
- Allogeneic Stem Cell Transplant, Chemotherapy
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1617
- NCT Identifier
- NCT02143830
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.